Developer docs
API playgroundTry for free, no card

Search company profiles

Intrepid Labs

Full company profile

uuid0000w18

Namestring
Intrepid Labs
Legal namestring
Intrepid Labs Inc.
Company typeenum
Private
Founded yearint
2023
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersToronto, Canada
HQ citystring
Toronto
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI drug formulation, pharmaceutical machine learning, autonomous laboratory systems, drug development robotics, formulation optimization platform
Industry4 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAG
Lab Automation, Instrument Control & Workflow Orchestration Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAIAD
Liquid Handling & Laboratory Automation (Pipettes, Robots, Workstations)
SECONDARYHLACAMAK
Lab Analytics, Utilization Management & Operational Intelligence
Healthcare & Life Sciences/Digital Health & Health IT/Laboratory Information Systems (LIS/LIMS) & Pathology Informatics
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Analytical Laboratory Instrument Manufacturing334516
  • Scientific Research and Development Services5417
SIC code2 codes
  • Laboratory Analytical Instruments3826
  • Services-Prepackaged Software7372
Product category
AI-Driven Drug Formulation Software
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Platform Licensing and Technology Services
TypeSubscription Recurring
Description

Multi-year strategic partnerships providing access to Intrepid's ML platforms (ANDROMEDA, VALIANT) for pharmaceutical formulation development. Revenue generated through partnership agreements with drug development companies.

contractpharma.com
2Collaborative Development
TypeProfessional Services
Description

Revenue from collaborative development projects with pharmaceutical partners, combining Intrepid's AI/ML capabilities with partner platforms. Pilot projects followed by wider rollout across formulation development workflows.

contractpharma.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 2 records shown
1VALIANT
Description

Intrepid's proprietary platform that harnesses AI and robotics to enable accelerated development of fully optimized formulations of drugs. It is a modular, autonomous laboratory that leverages data-driven experiment planning to optimize formulation compositions.

intrepidlabs.tech
+1 more record
Core offering1 text field

Intrepid Labs builds and licenses AI- and robotics-powered platforms (VALIANT and ANDROMEDA) that automate drug formulation development. The closed-loop system uses active machine learning to plan, prepare, and characterize formulation candidates in parallel, enabling pharmaceutical and biotech partners to accelerate formulation optimization, reduce API consumption, and shorten pre-clinical timelines.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Reduces drug formulation development time by up to 50%
+4 more records
Product overview1 text field

Intrepid Labs offers a proprietary AI and robotics platform for accelerated drug formulation development. The core technology consists of VALIANT, a modular autonomous laboratory platform that uses AI and robotics to optimize drug formulations in parallel, combined with the ANDROMEDA machine learning platform for formulation design and optimization. The company also provides the Intrepid Dashboard for customers to access their formulation data. These products work together to reduce development timelines from months to days by leveraging active learning and robotic automation.

Product and service2 records
1VALIANT
CategoryAutonomous laboratory / formulation platform
Description

VALIANT is a modular, autonomous laboratory platform that combines active machine learning with advanced robotics to plan, prepare, and characterize drug formulation candidates in parallel. It is targeted at pharmaceutical and biotech companies seeking to accelerate formulation optimization and reduce development timelines and API consumption across diverse formulation types including injectable depots, solid dosage forms, and nanoparticles.

2ANDROMEDA
CategoryMachine learning platform
Description

ANDROMEDA is a machine learning platform for formulating and optimizing clinical drug products. It uses active learning to rapidly explore formulation options, reduce experimental burden, minimize drug substance demands, and enhance data-driven decision-making. It is deployed via a secure independent AI instance per project to ensure data protection, and was commercialized through the multi-year strategic partnership with Quotient Sciences.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-12-04
Description

Multi-year strategic partnership to advance AI in early drug development. Combines Quotient's Translational Pharmaceutics platform with Intrepid's ANDROMEDA ML platform. After two years of collaboration, companies report they can save up to 50% of formulation development time and achieve comparable reductions in API usage. Initial pilot projects comparing traditional and AI-assisted methods will begin immediately, with plans for wider rollout following evaluation. A secure independent AI instance is deployed for each project to ensure data protection. This partnership culminated in the first reported AI-designed formulation entering Phase I clinical evaluation.

Strategic tierCoreTypeOthers
Description

Intrepid Labs is a JLABS resident company, providing access to JLABS' startup ecosystem, resources, and network within the pharmaceutical and biotech industry.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Member of the Vector Institute's Fast-Lane Program, providing access to Canada's leading AI research institute and talent network. Prof. Alán Aspuru-Guzik holds a CIFAR AI Chair at the Vector Institute.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Deep research partnership through the Acceleration Consortium, a strategic initiative at UofT that received a $200M grant in 2023 from the Canada First Research Excellence Fund. Multiple co-founders are professors at UofT. Co-founder Prof. Alán Aspuru-Guzik is Canada 150 Research Chair in Theoretical Chemistry at UofT.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Partnership with Mila (Quebec Artificial Intelligence Institute) providing access to additional AI research expertise and collaboration opportunities.

Strategic tierSupportingTypeOthers
Description

Partnership with MaRS Discovery District, Toronto's innovation hub. Intrepid Labs' headquarters is located at MaRS Centre.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Co-founded by Alán Aspuru-Guzik, Kebotix applies AI and robotics to chemistry and materials discovery — closely overlapping Intrepid's active-learning-plus-automation formulation approach.

TypeDirect peer
Description

AI-driven drug discovery and crystal/prediction platform combining computation with robotic experimentation, targeting pharma R&D efficiency — directly comparable to Intrepid's VALIANT/ANDROMEDA stack.

TypeBroad incumbent
Description

Established computational chemistry and predictive modeling platform serving large pharma across discovery and development, providing broader but overlapping capabilities vs. Intrepid's focused formulation play.

TypeBroad incumbent
Description

Public, well-capitalized AI-driven drug discovery company combining high-throughput biology with ML — addresses the broader drug development funnel that Intrepid targets via formulation.

5Isomorphic Labs
TypeBroad incumbent
Description

Alphabet/DeepMind-backed computational drug design company using AI across the full drug development pipeline; broad incumbent in AI pharma R&D.

TypeEmerging player
Description

ML-driven drug discovery company combining high-throughput data generation with predictive models; targets similar pharma enterprise buyers as Intrepid though focused earlier in discovery.

TypeEmerging player
Description

AI-driven drug discovery company using physics-informed ML for small molecule design; competing for the same enterprise AI-pharma partnerships.

TypeEmerging player
Description

AI-first biotech combining graph neural networks and lab-in-the-loop experimentation to accelerate small molecule discovery — overlapping lab-automation-and-ML paradigm with Intrepid.

TypeEmerging player
Description

AI platform for protein and biologics engineering with iterative wet-lab feedback, applying ML-plus-lab automation similar in spirit to Intrepid's formulation platform.

TypeOthers
Description

Cloud lab informatics platform (LIMS/ELN) widely used by pharma R&D — adjacent enabling technology rather than a direct competitor, but increasingly overlapping in AI-for-formulation workflows.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Intrepid Labs

AI-Driven Drug Formulation Softwareintrepidlabs.tech

Intrepid Labs firmographics

Firmographics
Name
Intrepid Labs
Legal name
Intrepid Labs Inc.
Website
https://intrepidlabs.tech
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Intrepid Labs industry classification

Industry
Product category
AI-Driven Drug Formulation Software
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Analytical Laboratory Instrument Manufacturing (334516), Scientific Research and Development Services (5417)
SIC
Laboratory Analytical Instruments (3826), Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAG
Lab Automation, Instrument Control & Workflow Orchestration Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAIAD
Liquid Handling & Laboratory Automation (Pipettes, Robots, Workstations)
SECONDARYHLACAMAK
Lab Analytics, Utilization Management & Operational Intelligence
Healthcare & Life Sciences/Digital Health & Health IT/Laboratory Information Systems (LIS/LIMS) & Pathology Informatics

Keywords

  • AI drug formulation
  • Pharmaceutical machine learning
  • Autonomous laboratory systems
  • Drug development robotics
  • Formulation optimization platform

Where Intrepid Labs is headquartered

Location

Headquarters

HQ city
Toronto
HQ country
Canada
HQ region
North America

Offices2 records

Markets served

Intrepid Labs business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Platform Licensing and Technology Services: Multi-year strategic partnerships providing access to Intrepid's ML platforms (ANDROMEDA, VALIANT) for pharmaceutical formulation development. Revenue generated through partnership agreements with drug development companies.
  2. Collaborative Development: Revenue from collaborative development projects with pharmaceutical partners, combining Intrepid's AI/ML capabilities with partner platforms. Pilot projects followed by wider rollout across formulation development workflows.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Intrepid Labs product offering

Product offering

Core offering

Intrepid Labs builds and licenses AI- and robotics-powered platforms (VALIANT and ANDROMEDA) that automate drug formulation development. The closed-loop system uses active machine learning to plan, prepare, and characterize formulation candidates in parallel, enabling pharmaceutical and biotech partners to accelerate formulation optimization, reduce API consumption, and shorten pre-clinical timelines.

Product overview

Intrepid Labs offers a proprietary AI and robotics platform for accelerated drug formulation development. The core technology consists of VALIANT, a modular autonomous laboratory platform that uses AI and robotics to optimize drug formulations in parallel, combined with the ANDROMEDA machine learning platform for formulation design and optimization. The company also provides the Intrepid Dashboard for customers to access their formulation data. These products work together to reduce development timelines from months to days by leveraging active learning and robotic automation.

Differentiator

Problem solved

Functional benefit

Brands

  • VALIANT: Intrepid's proprietary platform that harnesses AI and robotics to enable accelerated development of fully optimized formulations of drugs. It is a modular, autonomous laboratory that leverages data-driven experiment planning to optimize formulation compositions.
  • ANDROMEDA

Products and services

  • VALIANT VALIANT is a modular, autonomous laboratory platform that combines active machine learning with advanced robotics to plan, prepare, and characterize drug formulation candidates in parallel. It is targeted at pharmaceutical and biotech companies seeking to accelerate formulation optimization and reduce development timelines and API consumption across diverse formulation types including injectable depots, solid dosage forms, and nanoparticles.
  • ANDROMEDA ANDROMEDA is a machine learning platform for formulating and optimizing clinical drug products. It uses active learning to rapidly explore formulation options, reduce experimental burden, minimize drug substance demands, and enhance data-driven decision-making. It is deployed via a secure independent AI instance per project to ensure data protection, and was commercialized through the multi-year strategic partnership with Quotient Sciences.

Quantifiable outcome

  • Reduces drug formulation development time by up to 50%
  • +4 more outcomes

Companies that use Intrepid Labs

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Intrepid Labs technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Intrepid Labs partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered flagship, core and supporting.

  • Quotient SciencesflagshipStrategic or Co-development Partner · 4 December 2025Multi-year strategic partnership to advance AI in early drug development. Combines Quotient's Translational Pharmaceutics platform with Intrepid's ANDROMEDA ML platform. After two years of collaboration, companies report they can save up to 50% of formulation development time and achieve comparable reductions in API usage. Initial pilot projects comparing traditional and AI-assisted methods will begin immediately, with plans for wider rollout following evaluation. A secure independent AI instance is deployed for each project to ensure data protection. This partnership culminated in the first reported AI-designed formulation entering Phase I clinical evaluation.
  • Johnson & Johnson Innovation - JLABScoreOthersIntrepid Labs is a JLABS resident company, providing access to JLABS' startup ecosystem, resources, and network within the pharmaceutical and biotech industry.
  • Vector InstitutecoreStrategic or Co-development PartnerMember of the Vector Institute's Fast-Lane Program, providing access to Canada's leading AI research institute and talent network. Prof. Alán Aspuru-Guzik holds a CIFAR AI Chair at the Vector Institute.
  • University of TorontocoreStrategic or Co-development PartnerDeep research partnership through the Acceleration Consortium, a strategic initiative at UofT that received a $200M grant in 2023 from the Canada First Research Excellence Fund. Multiple co-founders are professors at UofT. Co-founder Prof. Alán Aspuru-Guzik is Canada 150 Research Chair in Theoretical Chemistry at UofT.
  • Mila Quebec AI InstitutesupportingStrategic or Co-development PartnerPartnership with Mila (Quebec Artificial Intelligence Institute) providing access to additional AI research expertise and collaboration opportunities.
  • MaRS Discovery DistrictsupportingOthersPartnership with MaRS Discovery District, Toronto's innovation hub. Intrepid Labs' headquarters is located at MaRS Centre.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Intrepid Labs competitors and assessment

Company assessment

Direct peers

  • Kebotix: Co-founded by Alán Aspuru-Guzik, Kebotix applies AI and robotics to chemistry and materials discovery — closely overlapping Intrepid's active-learning-plus-automation formulation approach.
  • XtalPi: AI-driven drug discovery and crystal/prediction platform combining computation with robotic experimentation, targeting pharma R&D efficiency — directly comparable to Intrepid's VALIANT/ANDROMEDA stack.

Broad incumbents

  • Schrödinger: Established computational chemistry and predictive modeling platform serving large pharma across discovery and development, providing broader but overlapping capabilities vs. Intrepid's focused formulation play.
  • Recursion Pharmaceuticals: Public, well-capitalized AI-driven drug discovery company combining high-throughput biology with ML — addresses the broader drug development funnel that Intrepid targets via formulation.
  • Isomorphic Labs: Alphabet/DeepMind-backed computational drug design company using AI across the full drug development pipeline; broad incumbent in AI pharma R&D.

Emerging players

  • Insitro: ML-driven drug discovery company combining high-throughput data generation with predictive models; targets similar pharma enterprise buyers as Intrepid though focused earlier in discovery.
  • Iambic: AI-driven drug discovery company using physics-informed ML for small molecule design; competing for the same enterprise AI-pharma partnerships.
  • Genesis Therapeutics: AI-first biotech combining graph neural networks and lab-in-the-loop experimentation to accelerate small molecule discovery — overlapping lab-automation-and-ML paradigm with Intrepid.
  • Cradle: AI platform for protein and biologics engineering with iterative wet-lab feedback, applying ML-plus-lab automation similar in spirit to Intrepid's formulation platform.

Others

  • Benchling: Cloud lab informatics platform (LIMS/ELN) widely used by pharma R&D — adjacent enabling technology rather than a direct competitor, but increasingly overlapping in AI-for-formulation workflows.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Intrepid Labs social profiles

Digital presence

Intrepid Labs financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Intrepid Labs leadership team

Management profile

Number of profiles

Profiles9 records

Intrepid Labs funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Intrepid Labs M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Intrepid Labs

What does Intrepid Labs do?

Intrepid Labs builds and licenses AI- and robotics-powered platforms (VALIANT and ANDROMEDA) that automate drug formulation development. The closed-loop system uses active machine learning to plan, prepare, and characterize formulation candidates in parallel, enabling pharmaceutical and biotech partners to accelerate formulation optimization, reduce API consumption, and shorten pre-clinical timelines.

Is Intrepid Labs a public or private company?

Intrepid Labs is a private company. It is classified as venture growth investor backed and is currently operating.

When was Intrepid Labs founded?

Intrepid Labs was founded in 2023. It employs 11 to 50 people.

Where is Intrepid Labs based?

Intrepid Labs is headquartered in Toronto, Canada, in the North America region.

How does Intrepid Labs make money?

Two revenue lines are on record. Platform Licensing and Technology Services are the primary driver. The others are collaborative Development.

Who are Intrepid Labs's main competitors?

Direct peers on record are Kebotix and XtalPi. Broad incumbents are Schrödinger, Recursion Pharmaceuticals and Isomorphic Labs. Emerging players are Insitro, Iambic, Genesis Therapeutics and Cradle. Benchling is listed as an others.

Does Intrepid Labs have an API?

No public API is recorded for Intrepid Labs.

What industry is Intrepid Labs in?

Intrepid Labs's product category is AI-Driven Drug Formulation Software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAGAJAG, Lab Automation, Instrument Control & Workflow Orchestration Software. Its NAICS code is 541714 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PharmTechPharma Fundamentals: Utilizing AI in Drug DevelopmentThe article discusses the increasing use of artificial intelligence (AI) in drug development within the pharmaceutical industry, highlighting its role in shortening timelines and optimizing the drug discovery process. It details regulatory principles established by the FDA and EMA, and presents a real-world example of a strategic partnership between Quotient Sciences and Intrepid Labs to advance AI-guided formulation development. The article emphasizes the importance of high-quality data, regulatory engagement, and maintaining human oversight for successful AI integration.Scientist LivePhase I Clinical Trial for AI-Designed Drug FormulationQuotient Sciences has initiated a Phase I clinical study at its UK facility to evaluate an AI-designed oral solid dose formulation, following approval from the MHRA. The trial, which uses Intrepid Labs' machine learning algorithm, aims to validate AI's potential to accelerate drug formulation development and improve clinical decision-making. The company claims this is the first reported case of an AI-designed formulation entering clinical evaluation, marking a milestone in AI-enabled pharmaceutical development.PR NewswireQuotient Sciences Advances AI-Designed Drug Product into Clinical DevelopmentQuotient Sciences initiated a Phase I clinical study of an AI-designed oral solid dose formulation in healthy volunteers, approved by the MHRA. The study aims to validate AI in drug product development, marking the first reported case of an AI-designed formulation in clinical trials. The company expects further updates over the coming months.ContractpharmaAI-Designed Drug Enters Phase I TrialQuotient Sciences has initiated a Phase I clinical trial at its UK facility for a novel oral drug product developed using artificial intelligence, following MHRA approval. The company claims this represents the first reported case of an AI-designed formulation being evaluated clinically. The study utilized Intrepid Labs' machine learning algorithms to optimize formulation design and will assess safety and pharmacokinetics in healthy volunteers.ContractpharmaHow AI Is Reshaping Early Drug Development Through a Landmark PartnershipQuotient Sciences, a global drug development and manufacturing accelerator, and Intrepid Labs, an AI leader in pharmaceutical formulation science, announced a multi-year strategic partnership to advance AI in early drug development, combining Quotient's Translational Pharmaceutics platform with Intrepid's machine learning model ANDROMEDA. After two years of collaboration, the companies report they can save up to 50% of formulation development time and achieve comparable reductions in API usage, while also building in silico predictive models that support more informed decision-making throughout development. The partnership represents an effort to address the high failure rate in drug development, where more than $100 billion is spent globally each year yet 90% of molecules still fail in clinical trials.PermiraQuotient Sciences and Intrepid Labs form strategic partnership to accelerate AI-guided formulation developmentQuotient Sciences and Intrepid Labs have announced a multi-year strategic partnership to advance AI use in early drug development, with Quotient gaining access to Intrepid's ANDROMEDA machine learning platform for formulation optimization. The AI platform aims to reduce experimental burden, minimize drug substance demands, and enhance data-driven decision-making in drug product development, with pilot projects beginning immediately followed by wider rollout. According to Boston Consulting Group analysis cited in the article, AI-enabled approaches could reduce time and cost in early development by 25-50%.Scientist LiveQuotient Sciences and Intrepid Labs partner to advance AI in early drug developmentQuotient Sciences and Intrepid Labs have established a multi-year strategic partnership aimed at advancing the use of AI in early drug development. This collaboration allows Quotient Sciences to utilize Intrepid's AI platform, Andromeda, to optimize drug formulation processes, reducing material needs and enhancing data-driven decisions. The partnership builds on an existing relationship and is expected to improve the efficiency and outcomes of drug development.Bio-itworldQuotient Sciences and Intrepid Labs form strategic partnership to accelerate AI-guided formulation developmentQuotient Sciences and Intrepid Labs announced a multi-year strategic partnership to advance AI use in early drug development, with Quotient gaining access to Intrepid's ANDROMEDA machine learning platform for formulating and optimizing clinical drug products. The partnership builds on an existing collaboration and will initially focus on pilot projects comparing traditional and AI-assisted formulation methods, with a secure independent AI instance for each project to ensure data protection. Industry analysis from Boston Consulting Group suggests AI-enabled approaches could reduce time and cost in early drug development by 25–50%.PR NewswireQuotient Sciences and Intrepid Labs form strategic partnership to accelerate AI-guided formulation developmentQuotient Sciences and Intrepid Labs announced a multi-year strategic partnership to advance AI use in early drug development, with Quotient Sciences gaining access to Intrepid's machine learning platform ANDROMEDA. The AI platform supports rapid exploration of formulation options to reduce experimental burden, minimize drug substance demands, and enhance data-driven decision-making. Initial pilot projects comparing traditional and AI-assisted methods will begin immediately, with both companies planning to explore additional applications as the partnership evolves.ContractpharmaQuotient Sciences, Intrepid Labs Partner to Advance AI in Early Drug DevelopmentQuotient Sciences and Intrepid Labs have announced a multi-year strategic partnership to advance AI in early drug development, with Quotient gaining access to Intrepid's machine learning platform ANDROMEDA. The AI platform supports rapid exploration of formulation options to reduce experimental burden, minimize drug substance demands, and enhance data-driven decision-making in clinical drug development. Initial pilot projects comparing traditional and AI-assisted methods will begin immediately, with plans for wider rollout following evaluation.